In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
 Stefan James
Speaker
Stefan James
Stefan James Stefan James

Uppsala University, Uppsala (Sweden)

Specialities : Interventional Cardiology , Acute Coronary Syndromes, Valvular Heart Disease, Research Methodology

Stefan James is Professor of Cardiology at Uppsala University, Scientific Director of Uppsala Clinical Research Center and a senior Interventional Cardiologist at Uppsala University Hospital Sweden. He is the president of the Swedish society of Cardiology and a Fellow of the ESC. Professor James co-chaired the previous and current 2017 ESC guidelines for ST-elevation myocardial infarction, co-author of several of the recent European guidelines on ACS and revascularization. Stefan James has served on executive steering committees for numerous international trials in cardiology. He has long served as the chairman of the SCAAR and a member of the steering committee of SWEDEHEART. He has pioneered the concept of registry based randomized clinical trials. His research has been published in over 400 peer-reviewed cardiology journals, and he is an associate editor of Circulation and an editorial board member for the EHJ and AHJ

42 presentations from this speaker

Acute coronary syndrome research in Circulation.

Event : ESC Congress 2019

  • Session : The new Circulation: expanding frontiers
  • Speaker : S James (Uppsala,SE)
  • Organised with the Circulation Journal

Changing the paradigm: registry-based randomized trials

Event : ESC Congress 2019

  • Session : Designing a clinical study - Learning from the masters
  • Speaker : S James (Uppsala,SE)

Creating a learning health care system of evidence generation by linking clinical registries, trials and biobanks

Event : ESC Congress 2019

  • Session : ESC Paul Hugenholtz Lecture for innovation
  • Speaker : S James (Uppsala,SE)

Discussant review - COMPLETE.

Event : ESC Congress 2019

  • Session : Hot Line Session 1
  • Speaker : S James (Uppsala,SE)

Effects in various clinical settings, patient subsets and healthcare realities

Event : ESC Congress 2019

  • Session : Intensive platelet inhibition in acute coronary syndromes - Where are we a decade after PLATO study results? (EBAC Accredited)
  • Speaker : S James (Uppsala,SE)
  • Supported by an unrestricted educational grant from AstraZeneca

Intensive platelet inhibition - Have we reached the ceiling or are there options for further development?

Event : ESC Congress 2019

  • Session : Intensive platelet inhibition in acute coronary syndromes - Where are we a decade after PLATO study results? (EBAC Accredited)
  • Speaker : L Wallentin (Uppsala,SE), R Mehran (New York,US), RF Storey (Sheffield,GB), C Cannon (Boston,US), S James (Uppsala,SE)
  • Supported by an unrestricted educational grant from AstraZeneca

STEMI patient with multivessel disease in shock - What do the Guidelines say.

Event : ESC Congress 2019

  • Session : Guidelines in Practice - Revascularisation strategies in STEMI and multivessel disease
  • Speaker : S James (Uppsala,SE)
  • Guidelines in Daily Practice

A STEMI patient on an oral anticoagulant due to a mitral valve prosthesis. - What do the Guidelines say?

Event : ESC Congress 2018

  • Session : Managing STEMI in patients on oral anticoagulation
  • Speaker : S James (Uppsala,SE)

Coronary interventional studies in Circulation

Event : ESC Congress 2018

  • Session : The New Circulation
  • Speaker : S James (Uppsala,SE)
  • Journal Circulation

Discussion - Residual cardiovascular risk after an acute coronary syndrome: identifying, stratifying and managing patients at long term risk of atherothrombotic cardiovascular events.

Event : ESC Congress 2018

  • Session : Residual cardiovascular risk after an acute coronary syndrome: identifying, stratifying and managing patients at long term risk of atherothrombotic cardiovascular events (EBAC Accredited)
  • Speaker : S James (Uppsala,SE), DJ Angiolillo (Jacksonville,US), SJ Nicholls (Adelaide,AU), M Bonaca (Boston,US)
  • Sponsored by AstraZeneca

Optimal management of long term cardiovascular risk in patients with multi-vessel coronary artery disease: a clinical case study.

Event : ESC Congress 2018

  • Session : Residual cardiovascular risk after an acute coronary syndrome: identifying, stratifying and managing patients at long term risk of atherothrombotic cardiovascular events (EBAC Accredited)
  • Speaker : S James (Uppsala,SE)
  • Sponsored by AstraZeneca

STEMI- Key message from the new guidelines.

Event : ESC Congress 2018

  • Session : Key messages from the most popular ESC webinars
  • Speaker : M Roffi (Geneva,CH), S James (Uppsala,SE)
  • ESC Education committee

Welcome and Introduction - Residual cardiovascular risk after an acute coronary syndrome: identifying, stratifying and managing patients at long term risk of atherothrombotic cardiovascular events.

Event : ESC Congress 2018

  • Session : Residual cardiovascular risk after an acute coronary syndrome: identifying, stratifying and managing patients at long term risk of atherothrombotic cardiovascular events (EBAC Accredited)
  • Speaker : S James (Uppsala,SE)
  • Sponsored by AstraZeneca

AMI-STEMI - Part 1

Event : ESC Congress 2017

  • Session : ESC Guidelines 2017 - Overview
  • Speaker : S James (Uppsala,SE)

AMI-STEMI.

Event : ESC Congress 2017

  • Session : Meet the Guidelines task force - AMI-STEMI
  • Speaker : S James (Uppsala,SE)

Discussion - Dual antiplatelet therapy after an acute coronary syndrome: confronting the disparity between guidelines and clinical practice.

Event : ESC Congress 2017

  • Session : Dual antiplatelet therapy after an acute coronary syndrome: confronting the disparity between guidelines and clinical practice (EBAC Accredited)
  • Speaker : P Steg (Paris,FR), DJ Angiolillo (Jacksonville,US), S James (Uppsala,SE), R Mehran (New York,US)
  • Sponsored by AstraZeneca

Doubts with long-term DAPT after STEMI? What do new Guidelines/consensus documents teach us? What do the Guidelines say?

Event : ESC Congress 2017

  • Session : New ESC Clinical Practice Guidelines 2016/2017 - Clinical cases put into perspective
  • Speaker : S James (Uppsala,SE)

Early initiation of dual anti-platelet therapy following an acute coronary syndrome: a clinical case study.

Event : ESC Congress 2017

  • Session : Dual antiplatelet therapy after an acute coronary syndrome: confronting the disparity between guidelines and clinical practice (EBAC Accredited)
  • Speaker : S James (Uppsala,SE)
  • Sponsored by AstraZeneca

Early initiation of dual anti-platelet therapy following an acute coronary syndrome: the clinical reality.

Event : ESC Congress 2017

  • Session : Dual antiplatelet therapy after an acute coronary syndrome: confronting the disparity between guidelines and clinical practice (EBAC Accredited)
  • Speaker : S James (Uppsala,SE)
  • Sponsored by AstraZeneca

Open questions - Dual antiplatelet therapy after an acute coronary syndrome: confronting the disparity between guidelines and clinical practice.

Event : ESC Congress 2017

  • Session : Dual antiplatelet therapy after an acute coronary syndrome: confronting the disparity between guidelines and clinical practice (EBAC Accredited)
  • Speaker : R Mehran (New York,US), S James (Uppsala,SE)
  • Sponsored by AstraZeneca

PCI for STEMI – How to do it right.

Event : ESC Congress 2017

  • Session : STEMI
  • Speaker : S James (Uppsala,SE)

Welcome and general overview of 2017 STEMI Guidelines.

Event : ESC Congress 2017

  • Session : ESC Guidelines 2017 - AMI-STEMI
  • Speaker : S James (Uppsala,SE)

Discussion - Optimising antiplatelet therapy from first medical contact to discharge.

Event : ESC Congress 2016

  • Session : The clinical journey after an acute coronary syndrome: strategies for optimising antiplatelet therapy
  • Speaker : D Capodanno (Catania,IT), C Hamm (Bad Nauheim,DE), S James (Uppsala,SE), P Steg (Paris,FR), M Bonaca (Boston,US)
  • Organised by University Hospital, Umeå / Course Director: Prof Ulf Näslund / Supported by an unrestricted educational grant from AstraZeneca

Discussion - The patient journey after an acute coronary syndrome - A clinical case study.

Event : ESC Congress 2016

  • Session : The clinical journey after an acute coronary syndrome: strategies for optimising antiplatelet therapy
  • Speaker : D Capodanno (Catania,IT), C Hamm (Bad Nauheim,DE), S James (Uppsala,SE), P Steg (Paris,FR), M Bonaca (Boston,US)
  • Organised by University Hospital, Umeå / Course Director: Prof Ulf Näslund / Supported by an unrestricted educational grant from AstraZeneca

Discussion - Who, when and why - The rationale to treat beyond 12 months.

Event : ESC Congress 2016

  • Session : The clinical journey after an acute coronary syndrome: strategies for optimising antiplatelet therapy
  • Speaker : D Capodanno (Catania,IT), C Hamm (Bad Nauheim,DE), S James (Uppsala,SE), P Steg (Paris,FR), M Bonaca (Boston,US)
  • Organised by University Hospital, Umeå / Course Director: Prof Ulf Näslund / Supported by an unrestricted educational grant from AstraZeneca

NorStent - Discussant review.

Event : ESC Congress 2016

  • Session : Hot Line coronary artery disease and stenting
  • Speaker : S James (Uppsala,SE)

Open questions - The clinical journey after an acute coronary syndrome: strategies for optimising antiplatelet therapy.

Event : ESC Congress 2016

  • Session : The clinical journey after an acute coronary syndrome: strategies for optimising antiplatelet therapy
  • Speaker : P Steg (Paris,FR), S James (Uppsala,SE), M Bonaca (Boston,US)
  • Organised by University Hospital, Umeå / Course Director: Prof Ulf Näslund / Supported by an unrestricted educational grant from AstraZeneca

The patient journey after an acute coronary syndrome - A clinical case study.

Event : ESC Congress 2016

  • Session : The clinical journey after an acute coronary syndrome: strategies for optimising antiplatelet therapy
  • Speaker : S James (Uppsala,SE)
  • Organised by University Hospital, Umeå / Course Director: Prof Ulf Näslund / Supported by an unrestricted educational grant from AstraZeneca

Welcome and introduction - The clinical journey after an acute coronary syndrome: strategies for optimising antiplatelet therapy.

Event : ESC Congress 2016

  • Session : The clinical journey after an acute coronary syndrome: strategies for optimising antiplatelet therapy
  • Speaker : S James (Uppsala,SE)
  • Organised by University Hospital, Umeå / Course Director: Prof Ulf Näslund / Supported by an unrestricted educational grant from AstraZeneca

Optimal initiation of dual anti-platelet therapy – Reviewing the evidence. Discussion.

Event : ESC Congress 2015

  • Session : Dual anti-platelet therapy in 2015 – Reviewing the evidence
  • Speaker : S James (Uppsala,SE)
  • Organised by The Sahlgrenska Academy - Goteborg University Course Director: Karl Swedberg Supported by an unrestricted educational grant from AstraZeneca

To stent or not to stent vulnerable lesions in stable coronary artery disease.

Event : ESC Congress 2015

  • Session : Preventive interventional cardiology: a dream coming true?
  • Speaker : S James (Uppsala,SE)

Incidence of stent thrombosis in registries and randomised trials.

Event : ESC Congress 2014

  • Session : New insights in stent thrombosis
  • Speaker : S James (Uppsala,SE)

PLATO in 2014: personalising treatment with ticagrelor.

Event : ESC Congress 2014

  • Session : Back in Barcelona with PLATO: 5 years of science, guidelines, practice and controversies
  • Speaker : S James (Uppsala,SE)
  • Sponsored by AstraZeneca

Pre-treatment with P2Y12 inhibitors in acute coronary syndrome. PRO.

Event : ESC Congress 2014

  • Session : Anticoagulants and antiplatelets - new perspectives
  • Speaker : S James (Uppsala,SE)

Pre-treatment with P2Y12 inhibitors in acute coronary syndrome. REBUTTAL PRO.

Event : ESC Congress 2014

  • Session : Anticoagulants and antiplatelets - new perspectives
  • Speaker : S James (Uppsala,SE)

Round table discussion - PLATO in 2014: personalising treatment with ticagrelor.

Event : ESC Congress 2014

  • Session : Back in Barcelona with PLATO: 5 years of science, guidelines, practice and controversies
  • Speaker : S James (Uppsala,SE)
  • Sponsored by AstraZeneca

State of the Art lecture: "Innovation in acute coronary syndromes"

Event : ESC Congress 2014

  • Session : State of the Art - Innovation in acute coronary syndromes
  • Speaker : S James (Uppsala,SE)

How do guidelines counteract utilisation of approved therapies?

Event : ESC Congress 2013

  • Session : Underutilisation of novel antiplatelet agents. What went wrong?
  • Speaker : S James (Uppsala,SE)

New oral antiplatelet drugs and risk of bleeding.

Event : ESC Congress 2013

  • Session : Antiplatelet and antithrombotic therapy after drug-eluting stents: what is next?
  • Speaker : S James (Uppsala,SE)

ST-elevation myocardial infarction: implementation of evidence-based treatments - are we doing enough?

Event : ESC Congress 2013

  • Session : ST-elevation myocardial infarction 2013
  • Speaker : S James (Uppsala,SE)

TASTE: Prospective Registry based Randomized Clinical Trials (RRCT) - a new concept for clinical research

Event : ESC Congress 2013

  • Session : Clinical Trial Update Hot Line III: Updates on risk and outcome
  • Speaker : S James (Uppsala,SE)

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are